QTERNMET XR
PeakNDAORALTABLET, EXTENDED RELEASE
Approved
May 2019
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
QTERNMET XR is an oral extended-release small molecule tablet approved by AstraZeneca in May 2019. The specific mechanism of action and therapeutic indication are not disclosed in available data, but the XR formulation suggests chronic disease management. This is a branded NDA product currently in peak commercial lifecycle.
Peak5.0 years to LOE
Product is at peak commercial stage with mature market penetration; sales teams are optimizing existing business rather than driving new adoption.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
QTERNMET XR offers mid-career stability in a mature product portfolio, with focus on optimizing market share and defending against generic entry. Roles emphasize commercial excellence, payer relations, and organizational efficiency rather than product innovation or launch excitement.
Brand ManagerSenior Brand Manager
Worked on QTERNMET XR at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.